Background: Probiotics are live microbial supplements that colonize the gut and potentially exert health benefit to the host. Objectives: We aimed to determine the impact of a probiotic (Infloran®: Lactobacillus acidophilus-NCIMB701748 and Bifidobacterium bifidum-ATCC15696) on the bacterial and metabolic function of the preterm gut while in the neonatal intensive care unit (NICU) and following discharge. Methods: Stool samples (n = 88) were collected before, during, and after probiotic intake from 7 patients, along with time-matched controls from 3 patients. Samples were also collected following discharge home from the NICU. Samples underwent bacterial profiling analysis by 16S rRNA gene sequencing and quantitative PCR (qPCR), as well as metabolomic profiling using liquid chromatography mass spectrometry. Results: Bacterial profiling showed greater Bifidobacterium (15.1%) and Lactobacillus (4.2%) during supplementation compared to the control group (4.0% and 0%, respectively). While Lactobacillus became reduced after the probiotic had been stopped, Bifidobacterium remained high following discharge, suggestive of successful colonisation. qPCR analysis showed a significant increase (p ≤ 0.01) in B. bifidum in infants who received probiotic treatment compared to controls, but no significant increase was observed for L. acidophilus (p = 0.153). Metabolite profiling showed clustering based on receiving probiotic or matched controls, with distinct metabolites associated with probiotic administration. Conclusions: Probiotic species successfully colonise the preterm gut, reducing the relative abundance of potentially pathogenic bacteria, and effecting gut functioning. Bifidobacterium (but not Lactobacillus) colonised the gut in the long term, suggesting the possibility that therapeutically administered probiotics may continue to exert important functional effects on gut microbial communities in early infancy.

Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al: Expert consensus document: the International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014;11:506-514.
Julia CA, Ermentrout GB, Jeffrey SU, Yoram V, Jonathan ER: Using a mathematical model to analyze the role of probiotics and inflammation in necrotizing enterocolitis. PLoS One 2010;5:e10066.
Gaul J: Probiotics for the prevention of necrotizing enterocolitis. Neonatal Netw 2008;27:75-80.
Berrington JE, Stewart CJ, Cummings SP, Embleton ND: The neonatal bowel microbiome in health and infection. Curr Opin Infect Dis 2014;27:236-243.
Ofek Shlomai N, Deshpande G, Rao S, Patole S: Probiotics for preterm neonates: what will it take to change clinical practice? Neonatology 2013;105:64-70.
Deshpande G, Patole S: Probiotic for preventing necrotising enterocolitis in preterm neonates -the past, present, and the future. East J Med 2013;15:168-174.
Berrington J, Stewart C, Embleton N, Cummings S: Gut microbiota in preterm infants: assessment and relevance to health and disease. Arch Dis Child Fetal Neonatal Ed 2013;98:F286-F290.
Yang Y, Guo Y, Kan Q, Zhou XG, Zhou XY, Li Y: A meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Braz J Med Biol Res 2014;47:804-810.
Morrow AL, Lagomarcino AJ, Schibler KR, Taft DH, Yu Z, Wang B, et al: Early microbial and metabolomic signatures predict later onset of necrotizing enterocolitis in preterm infants. Microbiome 2013;1:13.
Stewart CJ, Nelson A, Scribbins D, Marrs ECL, Perry JD, Embleton ND, et al: Bacterial and fungal viability in the preterm gut: NEC and sepsis. Arch Dis Child Fetal Neonatal Ed 2013;98:F298-F303.
Stewart C, Marrs E, Magorrian S, Nelson A, Lanyon C, Perry J, et al: The preterm gut microbiota: changes associated with necrotizing enterocolitis and infection. Acta Paediatr 2012;101:1121-1127.
Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD: Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. Appl Environ Microbiol 2013;79:5112-5120.
Tabasco R, Paarup T, Janer C, Peláez C, Requena T: Selective enumeration and identification of mixed cultures of Streptococcus thermophilus, Lactobacillus delbrueckii subsp. bulgaricus, L. acidophilus, L. paracasei subsp. paracasei and Bifidobacterium lactis in fermented milk. Int Dairy J 2007;17:1107-1114.
Matsuki T, Watanabe K, Fujimoto J, Takada T, Tanaka R: Use of 16S rRNA gene-targeted group-specific primers for real-time PCR analysis of predominant bacteria in human feces. Appl Env Microbiol 2004;70:7220-7228.
Eriksson L, Johansson E, Kettaneh-Wold N: Multi- and Megavariate Data Analysis. 2. Advanced Applications and Method Extensions. Malmö, MKS Umetrics AB, 2006.
Trivedi DK: The application of SIMCA P+ in shotgun metabolomics analysis of ZIC® HILIC-MS spectra of human urine - experience with the Shimadzu IT-T of and profiling solutions data extraction software. J Chromatogr Sep Tech 2012;3:145.
Jacobs SE, Tobin JM, Opie GF, Donath S, Tabrizi SN, Pirotta M, et al: Probiotic effects on late-onset sepsis in very preterm infants: a randomized controlled trial. Pediatrics 2013;132:1055-1062.
Stewart C, Skeath T, Nelson A, Fernstad S, Marrs E, Perry J, et al: Preterm gut microbiota and metabolome following discharge from intensive care. Sci Rep 2015;5:17141.
Barrett E, Guinane C: Microbiota diversity and stability of the preterm neonatal ileum and colon of two infants. Microbiologyopen 2013;2:2.
Wang R, Chen J: Early colonization of intestinal bifidobacteria and lactobacilli in the postoperative neonates with congenital intestinal atresia. Saudi Med J 2011;32:265-270.
Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, et al: Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci USA 2010;107:11971-11975.
Thompson-Chagoyan OC, Maldonado J, Gil A: Colonization and impact of disease and other factors on intestinal microbiota. Dig Dis Sci 2007;52:2069-2077.
Pärtty A, Luoto R, Kalliomäki M, Salminen S, Isolauri E: Effects of early prebiotic and probiotic supplementation on development of gut microbiota and fussing and crying in preterm infants: a randomized, double-blind, placebo-controlled trial. J Pediatr 2013;163:5.
Sim K, Shaw AG, Randell P, Cox MJ, McClure ZE, Li M-S, et al: Dysbiosis anticipating necrotizing enterocolitis in very premature infants. Clin Infect Dis 2015;60:389-397.
De la Cochetiere M-F, Piloquet H, des Robert C, Darmaun D, Galmiche J-P, Roze J-C: Early intestinal bacterial colonization and necrotizing enterocolitis in premature infants: the putative role of Clostridium. Pediatr Res 2004;56:366-370.
Stewart CJ, Marrs ECL, Nelson A, Lanyon C, Perry JD, Embleton ND, et al: Development of the preterm gut microbiome in twins at risk of necrotising enterocolitis and sepsis. PLoS One 2013;8:e73465.
Egan M, Motherway MO, Kilcoyne M, Kane M, Joshi L, Ventura M, et al: Cross-feeding by Bifidobacterium breve UCC2003 during co-cultivation with Bifidobacterium bifidum PRL2010 in a mucin-based medium. BMC Microbiol 2014;14:282.
Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Ley RE, Sogin ML, et al: A core gut microbiome in obese and lean twins. Nature 2009;457:480-484.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.